Torthaí cuardaigh - Jin‐Ji Yang
- 1 - 20 toradh as 54 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer de réir Wen‐Zhao Zhong, Xue‐Ning Yang, Jianling Bai, Jin‐Ji Yang, Christian Manegold, Yi‐Long Wu
Foilsithe / Cruthaithe 2008Revisão -
2
Multiple primary malignancies involving lung cancer de réir Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu
Foilsithe / Cruthaithe 2015Artigo -
3
Mutational landscape and characteristics of <scp>ERBB2</scp> in <scp>non‐small</scp> cell lung cancer de réir Xue‐Wu Wei, Xin Gao, Xu‐Chao Zhang, Jin‐Ji Yang, Zhihong Chen, Yi‐Long Wu, Qing Zhou
Foilsithe / Cruthaithe 2020Artigo -
4
Myocardial Extracellular Volume Fraction Measured by Cardiac Magnetic Resonance Imaging Negatively Correlates With Cardiomyocyte Breadth in a Healthy Porcine Model de réir Zhang, Shi-Jun, Chang, Di, Jin, Ji-Yang, Wang, Ya-Ling, Wang, Lin, Wang, Yuan-Cheng, Wang, Zhen, Ju, Shenghong
Foilsithe / Cruthaithe 2022Téacs -
5
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance de réir Zhen Wang, Jin‐Ji Yang, Jie Huang, Junyi Ye, Xu‐Chao Zhang, Hai‐Yan Tu, Han Han‐Zhang, Yi‐Long Wu
Foilsithe / Cruthaithe 2017Artigo -
6
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib de réir Jin‐Hyoung Kang, Hua‐Jun Chen, Zheng Wang, Jing Liu, Bing Li, Tengfei Zhang, Zhenfan Yang, Yi‐Long Wu, Jin‐Ji Yang
Foilsithe / Cruthaithe 2017Artigo -
7
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations de réir Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang, Hai‐Yan Tu, Qing Zhou, Wei‐Bang Guo, Hong‐Hong Yan, Yi‐Long Wu
Foilsithe / Cruthaithe 2016Artigo -
8
Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC de réir Mei-Mei Zheng, Yang-Si Li, Hai‐Yan Tu, Ben‐Yuan Jiang, Jin‐Ji Yang, Qing Zhou, Chong‐Rui Xu, Xiaorong Yang, Yi‐Long Wu
Foilsithe / Cruthaithe 2020Artigo -
9
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803) de réir Yi‐Long Wu, Caicun Zhou, Ying Cheng, Shun Lü, G.-Y. Chen, Cheng Huang, Yulu Huang, Hong‐Hong Yan, Shengxiang Ren, Yao-Bin Liu, Jin‐Ji Yang
Foilsithe / Cruthaithe 2012Artigo -
10
BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification de réir Ben‐Yuan Jiang, Xuchao Zhang, Jian Su, Wei Meng, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Zhiyong Chen, Zhihong Chen, Zhi Xie, Shiliang Chen, Yi‐Long Wu
Foilsithe / Cruthaithe 2013Artigo -
11
Intervertebral disc regeneration using platelet-rich plasma-containing bone marrow-derived mesenchymal stem cells: A preliminary investigation de réir WANG, SHAN-ZHENG, JIN, JI-YANG, GUO, YU-DONG, MA, LIANG-YU, CHANG, QING, PENG, XIN-GUI, GUO, FANG-FANG, ZHANG, HAI-XIANG, HU, XIN-FENG, WANG, CHEN
Foilsithe / Cruthaithe 2016Téacs -
12
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression de réir Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Lucy Yin, Shejuan An, Jia-Yin Lin, Shiliang Chen, Zhi Xie, Mike Zhu, Xiaolin Zhang, Yi‐Long Wu
Foilsithe / Cruthaithe 2010Artigo -
13
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients de réir Si‐Yang Maggie Liu, Hao Sun, Jiaying Zhou, Guang‐Ling Jie, Zhi Xie, Yang Shao, Xian Zhang, Junyi Ye, Chunxiang Chen, Xu‐Chao Zhang, Qing Zhou, Jin‐Ji Yang, Yi‐Long Wu
Foilsithe / Cruthaithe 2020Artigo -
14
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial de réir Qing Zhou, Jin‐Ji Yang, Zhihong Chen, Xu‐Chao Zhang, Hong‐Hong Yan, Chong‐Rui Xu, Jian Su, Hua‐Jun Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu
Foilsithe / Cruthaithe 2016Artigo -
15
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R de réir E‐E Ke, Qing Zhou, Qiuyi Zhang, Jian Su, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Jin‐Ji Yang, Hai‐Yan Tu, Hong‐Hong Yan, Yichen Zhang, Feiyu Niu, Yi‐Long Wu
Foilsithe / Cruthaithe 2017Artigo -
16
Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients de réir Jian Su, Wen‐Zhao Zhong, Xu‐Chao Zhang, Ying Huang, Hong‐Hong Yan, Jin‐Ji Yang, Zhong‐Yi Dong, Zhi Xie, Qing Zhou, Xiao-sui Huang, Danxia Lu, Wenqing Yan, Yi‐Long Wu
Foilsithe / Cruthaithe 2017Artigo -
17
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status de réir Wen‐Zhao Zhong, Xue‐Ning Yang, Hong‐Hong Yan, Xu‐Chao Zhang, Jian Su, Zhihong Chen, Ri-Qiang Liao, Qiang Nie, Song Dong, Qing Zhou, Jin‐Ji Yang, Hai‐Yan Tu, Yi‐Long Wu
Foilsithe / Cruthaithe 2015Artigo -
18
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC de réir Si‐Yang Maggie Liu, Lan-ying Gou, Anna Li, Na-Na Lou, Hongfei Gao, Jian Su, Jin‐Ji Yang, Xu‐Chao Zhang, Yang Shao, Zhong‐Yi Dong, Qing Zhou, Wen‐Zhao Zhong, Yi‐Long Wu
Foilsithe / Cruthaithe 2016Artigo -
19
Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status de réir She-Juan An, Zhi Hong Chen, Jian Su, Xu‐Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony Mok, Yi‐Long Wu
Foilsithe / Cruthaithe 2012Artigo -
20
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclit... de réir Yi‐Long Wu, Nagahiro Saijo, Sumitra Thongprasert, James Chih‐Hsin Yang, Baohui Han, Benjamin Margono, B. Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin‐Ji Yang, Tony Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka
Foilsithe / Cruthaithe 2016Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Biology
Cancer research
Epidermal growth factor receptor
Genetics
Gene
Chemotherapy
Adenocarcinoma
Gefitinib
Pathology
Clinical endpoint
Erlotinib
Mutation
Confidence interval
Gastroenterology
Hazard ratio
Immunotherapy
KRAS
Phases of clinical research
Randomized controlled trial
Cisplatin
Colorectal cancer
Environmental health
Malignant pleural effusion
Osimertinib
Population